HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consolidation in the PBM Industry

Executive Summary

Some industry executives are wondering whether customers on the outpatient side-most notably, pharmacy benefit management companies-are preparing their own consolidation.

For companies selling products into the inpatient setting, arguably the most important development over the past three or four years has been the dramatic consolidation among hospital systems and groups: witness the emergence of Columbia/HCA and the merger of Premier, American Health Care Systems, and SunHealth.

Now, some industry executives are wondering whether customers on the outpatient side—most notably, pharmacy benefit management companies—are preparing their own consolidation. While no large scale consolidation has taken place yet, the consolidation theories stem from a number of recent, unrelated developments: recent rumors that Medco was going to acquire Prescription Solutions, the PBM arm of Pacificare; the recent events at Caremark (a takeover by Mullikin) and ValueRx (spun-off by ValueHealth into an independent company); and, more generally, continued high consolidation at higher levels of the managed care industry.

Some industry executives point to the ValueHealth move as a clear indication that the company is positioning its PBM for a sale and they question whether Mullikin, a physician practice management firm, will find much value in Caremark’s PBM operation in the long term. Company officials reportedly want Caremark for its prescription data, which they see as necessary for disease management. But whether you have to own a PBM to get that remains to be seen. Says one PBM executive, “We debated that one internally for a while. I think they’re going to wait to see how much money you make off the rebates. You can make good arguments on both sides [i.e., that Mullikin will sell the PBM and that it won’t]. In the end, we split 50/50.”

Of course, since Merck, SB, and Lilly picked off three of the largest PBMs a couple of years ago, large scale consolidation—to rival the Premier/AmHS/SunHealth merger in the hospital industry—is impossible. Says one industry executive, “I don’t think consolidation will be dramatic because there’s nobody that big anymore. But we may see some of the smaller PBMs go.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV000301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel